AVEO Pharmaceuticals

^{, Nasdaq: AVEO}

Developing a renal cell carcinoma drug similar to blockbuster Avastin.

Industry: Health Care

First Day Return: -0.1%

AVEO

Developing a renal cell carcinoma drug similar to blockbuster Avastin.

IPO News for AVEO Pharmaceuticals

AVEO quiet period ends April 20 04/15/10
Four IPOs test investor appetite, post mixed performances this week 03/12/10
AVEO Pharmaceuticals prices IPO at $9, below the $13-$15 range 03/11/10

IPO Data
IPO Date	03/11/2010
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$81
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.aveopharma.com
Headquarters	Cambridge, MA, United States
Founded	2001
Employees at IPO	n/a

IPO News for AVEO Pharmaceuticals

AVEO quiet period ends April 20 04/15/10
Four IPOs test investor appetite, post mixed performances this week 03/12/10
AVEO Pharmaceuticals prices IPO at $9, below the $13-$15 range 03/11/10

AVEO Pharmaceuticals (AVEO) Performance